- Home
- AORT
AORT
Artivion Inc.
as 11-17-2025 3:44pm EST
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.
| Founded: | 1984 | Country: | United States |
| Employees: | N/A | City: | KENNESAW |
| Market Cap: | 1.9B | IPO Year: | 1993 |
| Target Price: | $49.36 | AVG Volume (30 days): | 439.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.21 | EPS Growth: | N/A |
| 52 Week Low/High: | $21.97 - $48.04 | Next Earning Date: | 11-06-2025 |
| Revenue: | $422,646,000 | Revenue Growth: | 9.81% |
| Revenue Growth (this year): | 14.91% | Revenue Growth (next year): | 10.90% |
Stock Insider Trading Activity of Artivion Inc. (AORT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Stanton Marshall S. | AORT | SVP, Clinical & MD Affair | Nov 13 '25 | Sell | $45.86 | 4,993 | $228,968.99 | 56,641 | |
| Horton Amy | AORT | VP, Chief Accounting Officer | Nov 13 '25 | Sell | $45.86 | 3,482 | $159,677.56 | 141,380 | |
| Holloway Jean F | AORT | SVP, General Counsel | Nov 13 '25 | Sell | $45.86 | 5,761 | $264,187.94 | 163,408 | |
| Mackin James P | AORT | President & CEO | Nov 13 '25 | Sell | $45.86 | 34,210 | $1,568,802.18 | 800,993 | |
| Davis John E | AORT | Chief Commercial Officer | Nov 13 '25 | Sell | $45.86 | 6,563 | $300,966.05 | 198,842 | |
| Holloway Jean F | AORT | SVP, General Counsel | Nov 11 '25 | Sell | $46.18 | 10,000 | $461,800.00 | 163,408 | |
| Stanton Marshall S. | AORT | SVP, Clinical & MD Affair | Nov 10 '25 | Sell | $44.62 | 2,566 | $114,492.35 | 56,641 | |
| Horton Amy | AORT | VP, Chief Accounting Officer | Nov 10 '25 | Sell | $44.62 | 1,789 | $79,823.39 | 141,380 | |
| Holloway Jean F | AORT | SVP, General Counsel | Nov 10 '25 | Sell | $44.62 | 2,960 | $132,072.24 | 163,408 | |
| Mackin James P | AORT | President & CEO | Nov 10 '25 | Sell | $44.62 | 17,580 | $784,402.02 | 800,993 |
Latest Artivion Inc. News
AORT Breaking Stock News: Dive into AORT Ticker-Specific Updates for Smart Investing
Business Wire
2 months ago
The First National Bank & Trust Company of Newtown Expands Partnership with Comcast Business to Support Banking Across Bucks County, PA
Business Wire
2 months ago
Net Asset Value(s)
Benzinga
2 months ago
AMD Expands Cohere Partnership To Power Enterprise AI On Instinct Chips
Just Food
2 months ago
Utz Brands joins growing chorus of US food pledges to remove FD&Cs
AFP
2 months ago
AI optimism cheers up markets following Fed rate warning
Newsfile
2 months ago
Element One Hydrogen Announces Acquisition of Additional Hydrogen Properties
Associated Press Finance
2 months ago
Iran's president says US, Israeli attacks inflicted a 'grievous blow' on international trust and peace prospects
Benzinga
2 months ago
'They Want Their Own DoorDash, They're Gonna Be the Ones That Are Paying for It.' Influencer Defends Teaching Money by Making Her Tweens Cover Extras
Compare AORT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AORT Artivion Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.